Stock INTEG B INTEGRUM AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Integrum AB

Equities

INTEG B

SE0009807266

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:41 2024-05-21 am EDT 		5-day change 1st Jan Change
53 SEK -3.64% Intraday chart for Integrum AB -3.64% +16.10%
May. 15 Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu CI
May. 02 Integrum Expands Its Product Offering to the United Kingdom Market CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • The company is in a robust financial situation considering its net cash and margin position.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 1325 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
INTEGRUM AB Stock Integrum AB
+16.10% 94.82M -
SONOVA HOLDING AG Stock Sonova Holding AG
+2.51% 19.09B
A
COCHLEAR LIMITED Stock Cochlear Limited
+6.62% 13.98B
B
DEMANT A/S Stock Demant A/S
+13.18% 10.62B
B-
EYEBRIGHT MEDICAL TECHNOLOGY (BEIJING) CO., LTD. Stock Eyebright Medical Technology (Beijing) Co., Ltd.
-12.90% 2.24B -
EMBLA MEDICAL HF. Stock Embla Medical hf.
+4.19% 1.78B
B+
ANGELALIGN TECHNOLOGY INC. Stock Angelalign Technology Inc.
+25.11% 1.64B
D-
MODERN DENTAL GROUP LIMITED Stock Modern Dental Group Limited
+17.44% 639M -
ANGEL ROBOTICS CO., LTD. Stock Angel Robotics Co., Ltd.
0.00% 372M - -
DELCATH SYSTEMS, INC. Stock Delcath Systems, Inc.
+94.47% 223M -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. INTEG B Stock
  4. Ratings Integrum AB
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW